## DG051

Cat. No.:	HY-10825	
CAS No.:	929915-58-2	Q
Molecular Formula:	C <sub>21</sub> H <sub>25</sub> Cl <sub>2</sub> NO <sub>4</sub>	ОН
Molecular Weight:	426	
Target:	Aminopeptidase	
Pathway:	Metabolic Enzyme/Protease	CI H-CI
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)	

## SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 325 mg/mL (762.91 mM) \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.3474 mL	11.7371 mL	23.4742 mL
	5 mM	0.4695 mL	2.3474 mL	4.6948 mL
	10 mM	0.2347 mL	1.1737 mL	2.3474 mL

Please refer to the solubility information to select the appropriate solvent.

BIOEOGICAL ACTIVITY				
Description	DG051 is a potent leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis in the enzyme assay with an IC <sub>50</sub> =47 nM.			
IC <sub>50</sub> & Target	IC50: 47 nM (LTA4H) <sup>[1]</sup>			
In Vitro	DG051 is a potent inhibitor of LTA4H aminopeptidase activity against L-alanine p-nitroanilide (IC <sub>50</sub> =72 nM). DG051 inhibits human whole blood (HWB) with IC <sub>50</sub> of 37 nM. As applied within the context of LTA4H inhibitor design, the chemistry team is able to design a potent DG051(K <sub>d</sub> =26 nM) with high aqueous solubility (>30 mg/mL) and high oral bioavailability (>80% across species) that is currently undergoing clinical evaluation for the treatment of myocardial infarction and stroke <sup>[1]</sup> DG-051 is a first-in-class small molecule inhibitor of leukotriene A4 hydrolase (LTA4H), currently in Phase II clinical development for the prevention of heart attack <sup>[2]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES



[1]. Sandanayaka V, et al. Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy]phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. J Med Chem. 2010 Jan 28;53(2):573-85.

[2]. Enache LA, et al. Synthesis and structural assignment of two major metabolites of the LTA4H inhibitor DG-051. Bioorg Med Chem Lett. 2009 Nov 15;19(22):6275-9.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA